prulifloxacin has been researched along with Sensitivity and Specificity in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qin, W; Wang, X; Yang, Z; Zhao, H | 1 |
| Fan, G; Li, Z; Pan, Y; Wen, J; Wu, Y; Zhang, L | 1 |
| Choudhury, H; Das, A; Das, AK; Pal, TK; Roy, B | 1 |
| Raju, B; Raju, SS; Ramesh, M; Srinivas, R; Venkateswarlu, Y | 1 |
| Cochetti, I; Ferrante, L; Montanari, MP; Rossi, V; Tili, E; Varaldo, PE | 1 |
| Guo, L; Jin, X; Qi, M; Wang, P; Zhao, H | 1 |
| Chen, F; Li, L; Yu, F | 1 |
7 other study(ies) available for prulifloxacin and Sensitivity and Specificity
| Article | Year |
|---|---|
Capillary electrophoresis-chemiluminescence determination of norfloxacin and prulifloxacin.
Topics: Buffers; Cerium; Chromatography, High Pressure Liquid; Dioxolanes; Electrophoresis, Capillary; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Luminescent Measurements; Norfloxacin; Piperazines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Terbium | 2008 |
Determination of ulifloxacin, the active metabolite of prulifloxacin, in human plasma by a 96-well format solid-phase extraction and capillary zone electrophoresis.
Topics: Anti-Bacterial Agents; Dioxolanes; Electrophoresis, Capillary; Fluoroquinolones; Humans; Piperazines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2008 |
Development and validation of a liquid chromatography-tandem mass spectrometry method to determine ulifloxacin, the active metabolite of prulifloxacin in rat and rabbit plasma: application to toxicokinetic study.
Topics: Animals; Chromatography, High Pressure Liquid; Dioxolanes; Drug Stability; Fluoroquinolones; Linear Models; Male; Piperazines; Rabbits; Rats; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2011 |
Identification and characterization of stressed degradation products of prulifloxacin using LC-ESI-MS/Q-TOF, MSn experiments: development of a validated specific stability-indicating LC-MS method.
Topics: Chromatography, High Pressure Liquid; Dioxolanes; Drug Stability; Fluoroquinolones; Hydrolysis; Oxidation-Reduction; Photolysis; Piperazines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Technology, Pharmaceutical; Temperature | 2011 |
Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin.
Topics: Colony Count, Microbial; Culture Media, Conditioned; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Piperazines; Quinolones; Sampling Studies; Sensitivity and Specificity | 2005 |
Determination of the active metabolite of prulifloxacin in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Anti-Bacterial Agents; Calibration; Chromatography, Liquid; Dioxolanes; Fluoroquinolones; Humans; Piperazines; Quinolones; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2006 |
Determination of adenosine disodium triphosphate using prulifloxacin-terbium(III) as a fluorescence probe by spectrofluorimetry.
Topics: Adenosine Triphosphate; Buffers; Calibration; Dioxolanes; Fluorescent Dyes; Fluoroquinolones; Hydrogen-Ion Concentration; Kinetics; Pharmaceutical Preparations; Piperazines; Sensitivity and Specificity; Spectrometry, Fluorescence; Terbium | 2008 |